BUFFALO, N.Y., May 15, 2018 (GLOBE NEWSWIRE) — MimiVax LLC, a clinical-stage biotechnology company developing immunotherapeutics and targeted therapies for cancer treatment, today announced that interim results from a multicenter Phase II study of SurVaxM in patients with newly diagnosed glioblastoma (GBM) will be presented during a poster session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, in Chicago.
SurVaxM is an immunotherapy that was discovered at Roswell Park Comprehensive Cancer Center and is being developed by MimiVax. It targets survivin, a cell-survival protein present in most cancers, and is designed to control tumor growth and recurrence. SurVaxM, which has been awarded orphan drug designation by the US Food and Drug Administration, is currently being studied as a treatment for GBM and multiple myeloma.
The phase II study has been supported in large part by donations to Roswell Park and is underway at five sites: Roswell Park Comprehensive Cancer Center, the Cleveland Clinic, Dana-Farber Cancer Institute, Massachusetts General Hospital and Beth Israel Deaconess Medical Center.
The poster presentation details are as follows:
- Title: Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma
- Presenter: Dr. Manmeet Ahluwalia, MD, FACP
- Abstract Number: 2041
- Session Title: Central Nervous System Tumors
- Date and Time: Saturday, June 2, 2018 from 1:15 p.m. – 4:45 p.m. CT
- Location: Hall A
About MimiVax LLC:
MimiVax LLC is a clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutics and targeted therapies for cancer treatment. Its lead candidate, SurVaxM, an immunotherapy discovered at Roswell Park Comprehensive Cancer Center, is currently undergoing Phase II study in glioblastoma and Phase I study in multiple myeloma. For more information, visit www.mimivax.com.
About SurVaxM:
SurVaxM is a first-in-class, patented peptide mimic immunotherapy that targets survivin, a cell-survival protein present in 95 percent of glioblastomas and many other cancers. It has simultaneous dual mechanisms to stimulate patients’ own T-cell immunity and unique antibody-directed inhibition of the survivin pathway to control tumor growth and prevent recurrence. SurVaxM has demonstrated safety and tolerability in a Phase I study in patients with recurrent or progressive malignant glioma (brain tumors) and with support from the Roswell Park Alliance Foundation, has entered a Phase II clinical trial in adults with newly diagnosed glioblastoma at leading cancer centers, namely Roswell Park Comprehensive Cancer Center, Cleveland Clinic and Dana-Farber Cancer Institute. A Phase I clinical trial evaluating SurVaxM in combination with REVLIMID® (lenalidomide) as a maintenance therapy for adults with multiple myeloma has also been initiated with support from Celgene (marketer of REVLIMID®). Because survivin is present in most cancers, including multiple myeloma, melanoma, ovarian, renal, lymphoma, prostate and breast cancers, SurVaxM could have broad applicability to these cancers.
About Roswell Park:
Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@roswellpark.org.
Media Contact:
Peter Steinerman
516-641-8959
prsteinerman@gmail.com
